Printer Friendly

BARRY BLOOM TO RETIRE FROM PFIZER; JOHN NIBLACK NAMED EXECUTIVE VICE PRESIDENT -- R&D

 NEW YORK, June 9 /PRNewswire/ -- Barry M. Bloom, Ph.D., executive vice president for research and development of Pfizer Inc (NYSE: PFE), will retire from the company and its board of directors effective Sept. 1.
 John F. Niblack, Ph.D., president of Pfizer Central Research, has been elected executive vice president for R&D of the corporation effective Sept. 1. He will be responsible for Central Research as well as the Licensing and Development, Quality Control and Regulatory Affairs functions. He will be the senior science officer of the corporation, reporting directly to William C. Steere, Jr., chairman and chief executive officer of Pfizer Inc.
 George M. Milne, Jr., Ph.D., will succeed Dr. Niblack as president of Central Research, which is the global pharmaceutical, animal health and food science research organization of Pfizer Inc. The organization is responsible for the largest and most promising new drug pipeline in Pfizer history. Headquartered in Groton, Conn., it employs some 4,000 scientists and medical personnel around the world. Dr. Milne will report to Dr. Niblack.
 Craig Saxton, M.D., has been promoted to executive vice president of Central Research reporting to Dr. Milne. He will be responsible for worldwide development of products emerging from the company's R&D pipeline. Both Drs. Milne and Saxton have been elected vice presidents of Pfizer Inc.
 "It has been my pleasure to have worked closely with Dr. Bloom over two decades," said Mr. Steere. "I have seen first-hand how he has elevated the status of Pfizer research and clearly focused its efforts so that today it stands as the envy of the industry."
 After earning an S.B. in chemistry and a Ph.D. in organic chemistry from the Massachusetts Institute of Technology, Dr. Bloom joined Pfizer in 1952 as a research chemist. He served as a research supervisor and director of medicinal products before being named president of Central Research in 1971. That same year Dr. Bloom was elected a corporate officer of Pfizer Inc and was elected to the board of directors in 1973. In 1990, he was named senior vice president of Pfizer Inc, and was made executive vice president last year.
 Dr. Niblack joined Pfizer in 1967 after earning Ph.D. and M.S. degrees in biochemistry from the University of Illinois and a B.S. degree in chemistry from Oklahoma State University. He progressed through several management positions in new drug discovery operations, and was named vice president for medicinal products research in 1984. In 1986 he was named executive vice president of Central Research and was promoted to president in 1990, at which time he was also made a vice president of Pfizer Inc.
 Dr. Milne joined Pfizer in 1970 after earning a B.S. in chemistry from Yale University and a Ph.D. in organic chemistry from the Massachusetts Institute of Technology. He completed postdoctoral work in organic chemistry at Stanford University and pharmacology at the Medical College of Virginia. Dr. Milne progressed through several management positions in new drug discovery and was appointed vice president of Central Research in 1985. In 1988 he was named senior vice president, Research and Development, of Central Research.
 Dr. Saxton earned a B.S. in anatomy and an M.D. from Leeds University in the United Kingdom. He joined the Pfizer Clinical Research staff at the research facility in Sandwich, England, in 1976. After a series of promotions at Sandwich, Dr. Saxton was appointed senior associate medical director of International Pharmaceuticals in 1981 and moved to New York headquarters. In 1982, Dr. Saxton was named vice president, Medical, for International Pharmaceuticals. In 1988, Dr. Saxton returned to the Central Research division where he was appointed senior vice president, Clinical Research and development.
 Pfizer Inc is a research-based diversified health care company with global operations. The company reported sales of about $7.2 billion for 1992. This year, Pfizer expects to spend more than $1 billion on research and development.
 -0- 6/9/93
 /CONTACT: Brian McGlynn of Pfizer, 203-441-5448/
 (PFE)


CO: Pfizer Inc ST: New York, Connecticut IN: MTC SU: PER

SH-LR -- NY056 -- 0253 06/09/93 15:34 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 9, 1993
Words:689
Previous Article:THE TALK CHANNEL SET FOR FALL '94 LAUNCH BY MULTIMEDIA; CABLE VETERAN PAUL A. FITZPATRICK TO HEAD NEW CHANNEL
Next Article:WITCO DECLARES DIVIDEND
Topics:


Related Articles
PFIZER ANNOUNCES EXECUTIVE APPOINTMENTS
PFIZER ANNOUNCES EXECUTIVE APPOINTMENTS.
PFIZER NAMES B.J. ROBISON PRESIDENT, CONSUMER HEALTH CARE
PFIZER NAMES B.J. ROBISON PRESIDENT, CONSUMER HEALTH CARE
HERB RYAN ELECTED A CORPORATE OFFICER AND CORPORATE CONTROLLER OF PFIZER INC; CHANGES IN FINANCE DIVISIONS ANNOUNCED
PFIZER ANNOUNCES NEW EXECUTIVE RESPONSIBILITIES; TOMBROS MOVES TO V.P. FOR INVESTOR RELATIONS, SCHULZE NAMED V.P. FOR CORPORATE STRATEGIC PLANNING,...
DONALD R. CONKLIN AND BARRY M. BLOOM NAMED TO VERTEX BOARD OF DIRECTORS
INCYTE PHARMACEUTICALS APPOINTS NEW BOARD MEMBER
EDWARD C. BESSEY TO RETIRE AS VICE CHAIRMAN OF PFIZER AND PRESIDENT OF ITS U.S. PHARMACEUTICALS GROUP
PFIZER R&D PIPELINE TO SUSTAIN COMPANY INTO FUTURE COMPANY'S TOP SCIENTISTS TELL WALL STREET

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters